Learn More

HI-Bio™ leverages human genetic and immunological insights to deliver targeted therapies to patients with severe immune-mediated diseases (IMDs). With clinical-stage programs and pipeline, HI-Bio has the potential to address diseases across the immune landscape.

Leading clinical immunology into its next chapter.

HI-Bio Announces Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration for Primary Membranous Nephropathy (PMN)

Press Release

Meet the Team

Our team’s track record developing and commercializing therapies powers our work at the forefront of precision medicine.

large_TEAM Module_2023.png

medium_TEAM Module_2023.png

small_TEAM Module_2023.png

thumbnail_TEAM Module_2023.png

Driven to make an impact on the lives of patients with severe immune-mediated diseases? Excited to work as part of a collaborative team? Say ‘HI’ and let us get to know each other.

Leading clinical immunology into its next chapter.

Press Release

HI-Bio Announces Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration for Primary Membranous Nephropathy (PMN)

Who We Are

Join the Team